A. K. Minochkin
Research Subjects
A. K. Minochkin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Svetlana Viacheslavovna Apalko
City Hospital No. 40, St. Petersburg 197706, Russia
5 shared publications - Oleg S. Popov
City Hospital № 40 of Kurortny District
4 shared publications - Natalya N. Sushentseva
City Hospital No. 40, St. Petersburg 197706, Russia
3 shared publications - Sergey G. Shcherbak
Saint-Petersburg State University
3 shared publications - Vladimir Yuryevich Lobzin
S.M. Kirov Military Medical Academy
3 shared publications - Sergey G. Shcherbak
City Hospital №. 40
2 shared publications
Latest Publications
- 1 January 2026
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 47 (2)
A comparative study of circulating biomarkers in patients with COVID-19 and neurodegenerative diseases
- 1 January 2026
- Published by Geotar-Media Publishing Group in Immunologiya
- Vol. 47 (2)
A comparative study of circulating biomarkers in patients with COVID-19 and neurodegenerative diseases
- 27 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (4) , 43-53
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cerebrospinal fluid
Objective. To determine, evaluate, and analyze the diagnostic value of various laboratory biomarkers of Alzheimer’s disease (AD) in blood and cerebrospinal fluid (CSF). Material and methods. The concentrations of 93 potential biomarkers in plasma and CSF were studied in patients with AD at various stages (n=53) and independently in the group at the predementia stage (n=15). Results. Statistically significant correlations of various directions (p≤0.05) were found between the coefficients characterizing the amyloidosis and neurodegeneration (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) with markers associated with neuroinflammation, vascular disorders, angiogenesis, neuroimaging changes, and neuropsychological indicators. Previous studies of markers associated with inflammation in CSF in AD patients have shown mixed results, and no markers have been introduced into clinical practice so far. Many biomarkers associated with two classical pathogenetic links and other pathophysiological processes have been identified. Conclusion. Coefficients reflecting two main pathogenetic processes in CSF of AD patients (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) are the most informative for verifying two main links in the disease pathogenesis—amyloidogenesis and neurodegeneration. In the group of patients with amnestic mild cognitive impairment (aMCI), statistically significant relationships of cytokines associated with neuroinflammation, growth factors, and complement system protein with coefficients of amyloidosis and neurodegeneration in CSF, as well as PET, MRI, and neuropsychological tests were shown; therefore, these indicators can also be considered as potential diagnostic biomarkers of early stages and possible predictors of MCI conversion to dementia. Such markers as GFAP, apolipoprotein A1, GDF-15, IFN-γ, IL-5, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, VEGF, and complement C3 should be considered as objects for further research as biomarkers for early diagnosis.
- 27 May 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (4) , 43-53
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cerebrospinal fluid
Objective. To determine, evaluate, and analyze the diagnostic value of various laboratory biomarkers of Alzheimer’s disease (AD) in blood and cerebrospinal fluid (CSF). Material and methods. The concentrations of 93 potential biomarkers in plasma and CSF were studied in patients with AD at various stages (n=53) and independently in the group at the predementia stage (n=15). Results. Statistically significant correlations of various directions (p≤0.05) were found between the coefficients characterizing the amyloidosis and neurodegeneration (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) with markers associated with neuroinflammation, vascular disorders, angiogenesis, neuroimaging changes, and neuropsychological indicators. Previous studies of markers associated with inflammation in CSF in AD patients have shown mixed results, and no markers have been introduced into clinical practice so far. Many biomarkers associated with two classical pathogenetic links and other pathophysiological processes have been identified. Conclusion. Coefficients reflecting two main pathogenetic processes in CSF of AD patients (Aβ-42/Aβ-40, phTau181/Aβ-42, phTau181/oTau, oTau/Aβ-42) are the most informative for verifying two main links in the disease pathogenesis—amyloidogenesis and neurodegeneration. In the group of patients with amnestic mild cognitive impairment (aMCI), statistically significant relationships of cytokines associated with neuroinflammation, growth factors, and complement system protein with coefficients of amyloidosis and neurodegeneration in CSF, as well as PET, MRI, and neuropsychological tests were shown; therefore, these indicators can also be considered as potential diagnostic biomarkers of early stages and possible predictors of MCI conversion to dementia. Such markers as GFAP, apolipoprotein A1, GDF-15, IFN-γ, IL-5, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, VEGF, and complement C3 should be considered as objects for further research as biomarkers for early diagnosis.
- 27 March 2025
- Published by Alfmed LLC in Medical alphabet
- No. 2,p. 29-38
Biomarkers of neuroinflammation and microcirculatory dysfunction in Alzheimer's disease: a comprehensive assessment of the pathogenetic and diagnostic role
The aim of the study was to identify laboratory biomarkers of asthma that could be promising for research as diagnostic tools. Materials and methods. 52 patients with asthma and 59 patients in the control group without cognitive impairment were examined, in which the concentration of 103 potential biomarkers in blood plasma (111 people) and CSF (24 people) were studied. Results. Statistically significant differences (pConclusion. Our results indicate a significant role of neuroinflammation, vascular pathology, angiogenesis, and BBB dysfunction in the pathological process occurring in asthma, which were previously confirmed by various researchers. Pathogenetically based plasma biomarkers associated with various links in the pathogenesis of asthma have been identified. Biomarkers of lipid metabolism, such as Apo-A1, Apo-CII in the peripheral bloodstream can be considered as indicators of the vascular-neurodegenerative process. Pro-inflammatory cytokines (IFNa, IFNy, IL-15, IL-1a, IL-8, sTNFR-1, sTNFR-2, IL-12p70 (including its IL-12p40 subunit), IL-17a, sCD 40L, sgp130, IP10, endoglin) and anti-inflammatory biomarkers (G-CSF1, BMP9, complement C 4, D-dimer, EFG1, eotaxin, fractalkine, G-CSF, GM–CSF, GDF-15, IL-1RA, IL-4, MDC, MIP1 β, MIP4, P-selectin, PEDF, sCD 30, sICAM-1, sNCAM-1, sIL-2ra, sIL-4r, TGFa VEGF-C, alpha-1-antitrypsin) in blood plasma, they are promising candidates for future effective diagnostic laboratory biomarkers. The most promising biomarker seems to be interleukin 12 subunit 40 (IL-12p40), due to its increase in the plasma of patients with asthma in contrast to the control group and the greatest number of correlations of its plasma level with other biomarkers in CSF.
- 27 March 2025
- Published by Alfmed LLC in Medical alphabet
- No. 2,p. 29-38
Biomarkers of neuroinflammation and microcirculatory dysfunction in Alzheimer's disease: a comprehensive assessment of the pathogenetic and diagnostic role
The aim of the study was to identify laboratory biomarkers of asthma that could be promising for research as diagnostic tools. Materials and methods. 52 patients with asthma and 59 patients in the control group without cognitive impairment were examined, in which the concentration of 103 potential biomarkers in blood plasma (111 people) and CSF (24 people) were studied. Results. Statistically significant differences (pConclusion. Our results indicate a significant role of neuroinflammation, vascular pathology, angiogenesis, and BBB dysfunction in the pathological process occurring in asthma, which were previously confirmed by various researchers. Pathogenetically based plasma biomarkers associated with various links in the pathogenesis of asthma have been identified. Biomarkers of lipid metabolism, such as Apo-A1, Apo-CII in the peripheral bloodstream can be considered as indicators of the vascular-neurodegenerative process. Pro-inflammatory cytokines (IFNa, IFNy, IL-15, IL-1a, IL-8, sTNFR-1, sTNFR-2, IL-12p70 (including its IL-12p40 subunit), IL-17a, sCD 40L, sgp130, IP10, endoglin) and anti-inflammatory biomarkers (G-CSF1, BMP9, complement C 4, D-dimer, EFG1, eotaxin, fractalkine, G-CSF, GM–CSF, GDF-15, IL-1RA, IL-4, MDC, MIP1 β, MIP4, P-selectin, PEDF, sCD 30, sICAM-1, sNCAM-1, sIL-2ra, sIL-4r, TGFa VEGF-C, alpha-1-antitrypsin) in blood plasma, they are promising candidates for future effective diagnostic laboratory biomarkers. The most promising biomarker seems to be interleukin 12 subunit 40 (IL-12p40), due to its increase in the plasma of patients with asthma in contrast to the control group and the greatest number of correlations of its plasma level with other biomarkers in CSF.
- Open Access
- 1 September 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (11) , 3396
Biobank as a source of samples for determination of concentration reference ranges for cytokines, chemokines and growth factors circulating in the blood
Aim . To determine the reference ranges of concentrations of 38 cytokines, chemokines and growth factors, as well as to measure the content of these analytes in patients with neurodegenerative and cardiovascular diseases (CVDs) using biomaterial from the biobank repository. Material and methods . The study included 303 serum and plasma samples from 281 healthy donors, 242 samples from 224 patients with neurodegenerative diseases, and 164 samples from 152 patients with CVDs from the biobank of the of St. Petersburg City Hospital № 40. In all samples, the concentration of 38 cytokines, chemokines, and growth factors was determined by multiplex immunofluorescence assay. Results . Based on the measured concentrations in the group of healthy donors, non-parametric 95% reference ranges with 90% confidence intervals were calculated. For the majority of analytes, no sex and age differences were observed. In donors >65 years of age, the concentration of macrophage inflammatory protein-1-α was reduced and the levels of interleukin-8 and the chemokine interferon-inducible protein 10 were increased. Young donors (18-35 years) had lower levels of tumor necrosis factor-α. In groups with neurodegenerative and cardiovascular diseases, multiple deviations from the calculated reference values were found. Conclusion . Certain reference intervals are intended to evaluate the concentrations of cytokines, chemokines and growth factors determined in blood serum or plasma using Human Cytokine/Chemokine Magnetic Bead Panel 1 reagents (Merck, Millipore) on the MAGPIX system and do not imply a direct transfer to other analytical methods.
- 1 September 2022
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 21 (11) , 3396
Open AccessBiobank as a source of samples for determination of concentration reference ranges for cytokines, chemokines and growth factors circulating in the blood
Aim . To determine the reference ranges of concentrations of 38 cytokines, chemokines and growth factors, as well as to measure the content of these analytes in patients with neurodegenerative and cardiovascular diseases (CVDs) using biomaterial from the biobank repository. Material and methods . The study included 303 serum and plasma samples from 281 healthy donors, 242 samples from 224 patients with neurodegenerative diseases, and 164 samples from 152 patients with CVDs from the biobank of the of St. Petersburg City Hospital № 40. In all samples, the concentration of 38 cytokines, chemokines, and growth factors was determined by multiplex immunofluorescence assay. Results . Based on the measured concentrations in the group of healthy donors, non-parametric 95% reference ranges with 90% confidence intervals were calculated. For the majority of analytes, no sex and age differences were observed. In donors >65 years of age, the concentration of macrophage inflammatory protein-1-α was reduced and the levels of interleukin-8 and the chemokine interferon-inducible protein 10 were increased. Young donors (18-35 years) had lower levels of tumor necrosis factor-α. In groups with neurodegenerative and cardiovascular diseases, multiple deviations from the calculated reference values were found. Conclusion . Certain reference intervals are intended to evaluate the concentrations of cytokines, chemokines and growth factors determined in blood serum or plasma using Human Cytokine/Chemokine Magnetic Bead Panel 1 reagents (Merck, Millipore) on the MAGPIX system and do not imply a direct transfer to other analytical methods.
- Open Access
- 17 April 2022
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 14 (2) , 35-42
New potential biomarkers of Alzheimer's disease: markers of endothelial dysfunction and neuroinflammation.
Alzheimer's disease (AD) is the most common cause of dementia in the elderly. The aim of the work wasObjective: to determine the relationship between laboratory biomarkers in blood plasma and cerebrospinal fluid (CSF) in patients with AD and indicators of neuropsychological testing.Patients and methods. 52 patients with AD were examined, in which the concentration of 90 potential biomarkers were measured in blood plasma and CSF. Neuropsychological assessment included the Mini-Mental State Exam (MMSE), Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA), and etc.Results and discussion. Correlations of different strength between the values of biomarkers in blood plasma and CSF and the results of neuropsychological assessment were revealed. A correlation was found between the soluble cell adhesion molecule (sICAM-1) in blood plasma and the largest number of neuropsychological tests sensitive to dementia stages (MoCA, MMSE, FAB) in patients with AD at the dementia stage. A correlation was found between the concentration of growth/differentiation factor 15 and interferon γ in blood plasma and FAB scores in patients with AD. The levels of granulocyte colony-stimulating factor (G-CSF) in CSF were associated with the dementia stage in AD, and the interleukin-1 receptor antagonist (IL-1RA) levels, on the contrary, with stages preceding the development of dementia in AD.Conclusion. sICAM-1 level in blood plasma, which is a marker of endothelial dysfunction, may be an indicator of the severity of the vascular neurodegenerative process in AD at the dementia stage. G-CSF in the CSF is associated with the dementia stage in AD, and IL-1RA – with the pre-dementia stage of AD, which determines the prospect of their further study as diagnostic markers.
- 17 April 2022
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 14 (2) , 35-42
Open AccessNew potential biomarkers of Alzheimer's disease: markers of endothelial dysfunction and neuroinflammation.
Alzheimer's disease (AD) is the most common cause of dementia in the elderly. The aim of the work wasObjective: to determine the relationship between laboratory biomarkers in blood plasma and cerebrospinal fluid (CSF) in patients with AD and indicators of neuropsychological testing.Patients and methods. 52 patients with AD were examined, in which the concentration of 90 potential biomarkers were measured in blood plasma and CSF. Neuropsychological assessment included the Mini-Mental State Exam (MMSE), Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA), and etc.Results and discussion. Correlations of different strength between the values of biomarkers in blood plasma and CSF and the results of neuropsychological assessment were revealed. A correlation was found between the soluble cell adhesion molecule (sICAM-1) in blood plasma and the largest number of neuropsychological tests sensitive to dementia stages (MoCA, MMSE, FAB) in patients with AD at the dementia stage. A correlation was found between the concentration of growth/differentiation factor 15 and interferon γ in blood plasma and FAB scores in patients with AD. The levels of granulocyte colony-stimulating factor (G-CSF) in CSF were associated with the dementia stage in AD, and the interleukin-1 receptor antagonist (IL-1RA) levels, on the contrary, with stages preceding the development of dementia in AD.Conclusion. sICAM-1 level in blood plasma, which is a marker of endothelial dysfunction, may be an indicator of the severity of the vascular neurodegenerative process in AD at the dementia stage. G-CSF in the CSF is associated with the dementia stage in AD, and IL-1RA – with the pre-dementia stage of AD, which determines the prospect of their further study as diagnostic markers.